Publications:

Olaparib is effective for recurrent urothelial carcinoma with BRCA2 pathogenic germline mutation: first report on olaparib response in recurrent UC.

Therapeutic Advances In Medical Oncology

Yang, Hong H; Liu, Zhimin Z; Wang, Yufang Y; Li, Jun J; Li, Ruiqian R; Wang, Qilin Q; Hu, Chen C; Jiang, Haiyang H; Wu, Hongyi H; Song, Lele L; Bai, Yu Y

Publication Date: 2020

Variant appearance in text: RB1: 511C>G; L171V

PubMed Link: 33240400

Variant Present in the following documents:

• Main text
• 10.1177_1758835920970845.pdf

View BVdb publication page

Targeting YAP to overcome acquired resistance to ALK inhibitors in ALK-rearranged lung cancer.

Embo Molecular Medicine

Yun, Mi Ran MR; Choi, Hun Mi HM; Lee, You Won YW; Joo, Hyeong Seok HS; Park, Chae Won CW; Choi, Jae Woo JW; Kim, Dong Hwi DH; Kang, Han Na HN; Pyo, Kyoung-Ho KH; Shin, Eun Joo EJ; Shim, Hyo Sup HS; Soo, Ross A RA; Yang, James Chih-Hsin JC; Lee, Sung Sook SS; Chang, Hyun H; Kim, Min Hwan MH; Hong, Min Hee MH; Kim, Hye Ryun HR; Cho, Byoung Chul BC

Publication Date: 2019-12

Variant appearance in text: RB1: 511C>G; L171V

PubMed Link: 31633304

Variant Present in the following documents:

• EMMM-11-e10581-s001.pdf

View BVdb publication page